



## **UVI 3003**

Catalog No: tcsc0028638

Available Sizes
Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Specifications
<b>CAS No:</b> 847239-17-2
Formula: C <sub>28</sub> H <sub>36</sub> O <sub>4</sub>
<b>Pathway:</b> Metabolic Enzyme/Protease
Target: RAR/RXR
Purity / Grade: >98%
<b>Solubility:</b> 10 mM in DMSO
Observed Molecular Weight: 436.58

## **Product Description**

UVI 3003 is a highly selective antagonist of **retinoid X receptor (RXR)**, and inhibits xenopus and human **RXRα** in Cos7 cells, with **IC** 50





s of 0.22 and 0.24  $\mu$ M, respectively.

IC50 & Target: IC50: 0.22  $\mu$ M (Xenopus RXR $\alpha$ , in Cos7 cells), 0.24  $\mu$ M (Human RXR $\alpha$ , in Cos7 cells) [1]

In Vitro: UVI3003 inhibits the activity of xenopus and human RXR $\alpha$ , with IC $_{50}$ s of 0.22 and 0.24  $\mu$ M, respectively. UVI3003 fully activates xPPAR $\gamma$  with an EC $_{50}$  of 12.6  $\mu$ M, and is almost completely inactive on hPPAR $\gamma$  and mPPAR $\gamma$ <sup>[1]</sup>. UVI 3003 (10  $\mu$ M) does not change the proliferation rate of extraocular muscles (EOM)-derived or LEG-derived EECD34 cells. UVI 3003 causes a 65.4% difference in EECD34 cell fusion and desmin expression<sup>[2]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!